Comparative Risk of Incident and Recurrent Acute Anterior Uveitis across Different Biological Agents in Patients with Ankylosing Spondylitis
DOI 10.1093/rheumatology/keae003 Epub ahead of print
Kwon, et al. found that adalimumab exposure significantly reduced risk of incident and recurrent acute anterior uveitis (AAU) versus etanercept exposure and bDMARD non-exposure. Furthermore, exposure to etanercept significantly increased risk of incident and recurrent AAU versus bDMARD non-exposure.
This retrospective nationwide Korean cohort study compared the risk of AAU between different bDMARDs using data from the HIRA database. bDMARDs included in the study were adalimumab, etanercept, golimumab, infliximab, secukinumab and ixekizumab.
Keywords:
